









Markets
/
Stocks
/
nasdaq-cgem
/

Cullinan Therapeutics Inc

CGEM

12.230USD

+0.380+3.21%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

722.50MMarket Cap

LossP/E TTM



Cullinan Therapeutics Inc

12.230

+0.380+3.21%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cullinan Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cullinan Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 37 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 32.27.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cullinan Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

37 / 392

Overall Ranking

141 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cullinan Therapeutics Inc Highlights

StrengthsRisks

Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Fairly Valued

The company’s latest PE is -3.32, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 64.92M shares, increasing 4.72% quarter-over-quarter.

Held by HOTCHKIS & WILEY

Star Investor HOTCHKIS & WILEY holds 1.76K shares of this stock.

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

32.273

Target Price

+172.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cullinan Therapeutics Inc is 5.87, ranking 315 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is average.

Score

Industry at a Glance

Previous score

5.87

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.16

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cullinan Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cullinan Therapeutics Inc is 7.72, ranking 88 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.32, which is -408.29% below the recent high of 10.23 and -182.94% above the recent low of -9.39.

Score

Industry at a Glance

Previous score

7.72

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 37/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cullinan Therapeutics Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 53.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

32.273

Target Price

+172.34%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Cullinan Therapeutics Inc

CGEM

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cullinan Therapeutics Inc is 8.69, ranking 60 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 13.76 and the support level at 10.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.25

Change

1.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.007

Neutral

RSI(14)

56.041

Neutral

STOCH(KDJ)(9,3,3)

38.971

Sell

ATR(14)

0.890

High Vlolatility

CCI(14)

11.980

Neutral

Williams %R

40.268

Buy

TRIX(12,20)

0.716

Sell

StochRSI(14)

20.321

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

12.466

Sell

MA10

12.237

Sell

MA20

11.720

Buy

MA50

11.150

Buy

MA100

9.310

Buy

MA200

8.578

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cullinan Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 132.11%, representing a quarter-over-quarter increase of 1.53%. The largest institutional shareholder is The Vanguard, holding a total of 3.29M shares, representing 5.57% of shares outstanding, with 8.42% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lynx1 Capital Advisors LLC

8.96M

+55.45%

MPM BioImpact LLC

7.65M

BVF Partners L.P.

5.75M

BlackRock Institutional Trust Company, N.A.

3.68M

-0.39%

The Vanguard Group, Inc.

Star Investors

2.94M

-2.55%

Deerfield Management Company, L.P.

2.93M

-24.08%

Blue Owl Capital Holdings LP

2.51M

+5.24%

Kynam Capital Management LP

2.30M

+9.84%

Citadel Advisors LLC

1.98M

-34.05%

OrbiMed Advisors, LLC

1.92M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cullinan Therapeutics Inc is 3.49, ranking 140 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.